Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Trial details
- Registry ID
- NCT04544293
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293 | SVRA | Phase 3 | Active not recruiting | 2023-11-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |